Glottographic measures before and after levodopa treatment in Parkinson's disease.
OBJECTIVE
Investigate the usefulness of acoustic and glottographic measures for detecting effects of levodopa (L-dopa) treatment on vocal function of individuals with idiopathic Parkinson's disease.


METHODS
Compare recordings of vowels sustained at a target comfortable loudness level obtained before and after L-dopa treatment from 15 individuals with idiopathic Parkinson's disease showing signs of tremor.


METHODS
A simultaneous acoustic, airflow, and electroglottographic recording technique was employed to record vowels phonated by subjects before and after L-dopa treatment. Algorithms were developed to derive from the recorded signal measures of fundamental frequency, SPL airflow rate, speed quotient (ratio of glottal opening to closing time time), and short- and long-term phonatory instability. A series of paired Student t tests or signed rank tests were performed to compare the pretreatment and posttreatment groups on these measures.


RESULTS
Measures of speed quotient, acoustic shimmer (cycle-to-cycle amplitude perturbation), and the extent of tremor derived from acoustic intensity contours were found to significantly decrease after medication. Sound pressure level tended to increase after medication. The acoustic jitter (cycle-to-cycle frequency perturbation) and the extent of tremor derived from airflow signals did not significantly differentiate between premedication and postmedication voices.


CONCLUSIONS
Objective measures of acoustic and electroglottographic signals are useful in monitoring the pharmacologic response of Parkinson's disease, reflecting decrease of laryngeal rigidity and short- and long-term acoustic amplitude fluctuation after L-dopa treatment.
Jiang
J
J
Department of Otolaryngology-Head and Neck Surgery, Northwestern University School of Medicine, Chicago, Illinois, USA.
Lin
E
E
Wang
J
J
Hanson
D G
DG
D000368:Aged; D000369:Aged, 80 and over; D000465:Algorithms; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D004558:Electric Stimulation / Q000379:methods; D001330:Electronic Data Processing; D005260:Female; D005931:Glottis / Q000503:physiopathology*; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy*; D012984:Software; D013061:Speech Acoustics; D013068:Speech Production Measurement; D014202:Tremor / Q000175:diagnosis; D014832:Voice Disorders / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology
D000978:Antiparkinson Agents; D007980:Levodopa